Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis (NCT07572383)
Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Lung Fibrosis in Participants With Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital — Boston, Massachusetts
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Massachusetts General Hospital — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 724-4030
Email: sbmontesi@mgb.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Interstitial Lung Disease
- Genentech Validation Tool for Pulmonary Fibrosis — New York, New York
- FAPI PET for Lung Fibrosis — Los Angeles, California
- Interstitial Lung Disease Research Unit Biobank — Kansas City, Kansas
- Hyperpolarized 129Xe MRI for Imaging Pulmonary Function — Durham, North Carolina
- Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough — Rochester, Minnesota
- Pulmonary Hypertension SOLAR — Durham, North Carolina
Explore by condition: All Interstitial Lung Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.